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Abstract
Multiple sclerosis (MS) is a neurodegenerative disease characterized by demyelination and
inflammation. Dysregulated lipid metabolism and mitochondrial dysfunction are hypothe-
sized to play a key role in MS. Carnitine Palmitoyl Transferase 1 (CPT1) is a rate-limiting
enzyme for beta-oxidation of fatty acids in mitochondria. The therapeutic effect of pharma-
cological CPT1 inhibition with etomoxir was investigated in rodent models of myelin oligo-
dendrocyte glycoprotein- and myelin basic protein-induced experimental autoimmune
encephalitis (EAE). Mice receiving etomoxir showed lower clinical score compared to pla-
cebo, however this was not significant. Rats receiving etomoxir revealed significantly lower
clinical score and lower body weight compared to placebo group. When comparing etomoxir
with interferon-β (IFN-β), IFN-β had no significant therapeutic effects, whereas etomoxir
treatment starting at day 1 and 5 significantly improved the clinical scores compared to the
IFN-β and the placebo group. Immunohistochemistry and image assessments of brain sec-
tions from rats with EAE showed higher myelination intensity and decreased expression of
CPT1A in etomoxir-treated rats compared to placebo group. Moreover, etomoxir mediated
increased interleukin-4 production and decreased interleukin-17α production in activated T
cells. In conclusion, CPT1 is a key protein in the pathogenesis of EAE and MS and a crucial
therapeutic target for the treatment.
Introduction
One of the key functions of lipids in the CNS is to build and maintain the myelin sheath on the
axons of neurons, as well as to facilitate protein transfer from oligodendrocytes to the myelin
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sheaths [1,2]. It is well established that metabolism of lipids is significantly altered in multiple
sclerosis (MS) patients [3–7]. Previous studies that examined the lipid levels of MS, bipolar dis-
order or schizophrenia patients demonstrated a significant reduction in the mono-unsaturated
and saturated fatty acids lipid concentrations, specifically of 16:1 (palmitate) and 18:1 lipids
(oleate lipids) [8–10]. Although polyunsaturated fatty acid levels were not examined in these
studies, the shift in lipid levels was likely due to changes in metabolic pathways, such as switch
in the balance between the metabolism of glucose and of lipids. This metabolic redirection,
when occurring in the brain, leads to the reduced levels of poly- and mono-unsaturated and
saturated fatty acids in the myelin sheath and cerebral spinal fluid. Moreover, cholesterol levels
in the body are changed and correlate with MS progression [5,6]. Evidence supporting this
pathogenesis is shown by positron emission tomography analyses of MS lesions which reveal a
greatly reduced glucose metabolism [7,11].
In addition to lower levels of constitutional lipids, an upregulation of enzymes involved in
lipid metabolism has been identified in MS lesions. One of the most significant enzymes in the
metabolism of lipids is carnitine palmitoyl transferase 1A (CPT1A), which is abundantly
expressed in the brain and most organs where it catalyzes the rate-limiting step in beta-oxida-
tion. CPT1 is localized at the outer mitochondrial membrane, where it couples an acyl-carni-
tine group with lipids, and facilitates transport across the outer mitochondrial membrane.
After transport of acyl-carnitine, CPT2 localized at the inner mitochondrial membrane
removes the carnitine group from the lipid molecule which enables its degradation via beta-
oxidation. Biological systems switch their metabolism from glucose to lipid, i.e. enhanced
catabolism of lipids, under locally occurring hypoxic stress. This happens in order to prevent
overproduction of lactate and avoid the associated toxicity. Increased catabolism of lipids
under situations of stress induces local production of prostaglandin E2 (PGE2) [12], thereby
attracting and activating the immune system. Moreover, prolonged lipid catabolism activated
under hypoxia can result in mitochondrial dysfunction.
In the MS lesions, CPT1A expression is greatly increased [13], which correlates with a
decrease in lipid concentration in the myelin sheath due to an increased beta-oxidation. Loss
of lipids in the myelin sheath results in a functional impairment, manifested by increasing sig-
naling time and an escalation in energy expenditure. In addition, lipids provide a protective
function for the proteins expressed in the myelin sheath. If the lipids of the myelin sheath are
no longer functional or present at all, proteins in myelin such as myelin basic protein (MBP)
have some arginine’s converted to citrulline by peptidyl arginine deiminase, thereby making
them immunogenic [14–17]. Moreover, under hypoxic conditions lipid metabolism is associ-
ated with increased prostaglandin production [12,18], and enhanced chemotaxis of immune
cells to the exposed myelin sheath proteins.
Based on these mechanisms, we therefore hypothesize that blockage of CPT1A function
may result in both therapeutic and preventative effects in the progression of MS. To examine
this hypothesis, we studied the efficacy of the CPT1 blocker etomoxir for the treatment of
advanced experimental autoimmune encephalitis (EAE) in rodents [19]. The changes of MBP,
CPT1A and ferritin expression were examined in the EAE rat model. Moreover, the effect of
etomoxir on inflammation and production of cytokines were examined.
Materials and methods
Animals
All animal experiments were conducted according to NIH guidelines and were approved by
the Danish National Committee for Ethics in Animal Experimentation (2007/561-1364 and
2015-15-0201-00647). Six-week-old female C57BL/6 mice (n = 42) were bred and kept at
PLOS ONE Pharmacological inhibition of carnitine palmitoyl transferase 1 inhibits and reverses EAE in rodents
PLOS ONE | https://doi.org/10.1371/journal.pone.0234493 June 10, 2020 2 / 17
Funding: A grant from Lundbeckfonden, R191-
2015-1118, financed the studies. J.G.K.N. and S.N.
disclose being employed and have financial interest
in Meta-IQ. The funders provided support in the
form of the drug Etomoxir used in the animal study
as well as know-how on the drug, but did not have
any additional role in the study design, data
collection and analysis, decision to publish, or
preparation of the manuscript. The specific roles of
these authors are articulated in the ‘author
contributions’ section.
Competing interests: J.G.K.N. and S.N. declares
conflict of interest as owner of Meta-IQ ApS, who
provided the etomoxir for the study. This does not
alter our adherence to PLOS ONE policies on
sharing data and materials.
conventional animal facilities at the University of Copenhagen. Two-month-old female Lewis
rats (n = 42 and n = 55) were bred and kept at conventional animal facilities at the University
of Aarhus. All animals were maintained under standardized conditions of light and tempera-
ture, with a 12-h day/night cycle and food and water ad libitum. During the progression of
EAE leading to motor disabilities, animals had water in a petri dish and soaked chow for easy
intake to ensure sufficient liquid and nutrients intake.
Experimental autoimmune encephalomyelitis immunization
C57BL/6 mice were immunized subcutaneously (s.c.) in the flank with 200 μg of MOG35–55
peptide emulsified in complete Freund´s adjuvant (CFA) containing 0.1 mg Mycobacterium
tuberculosis (Becton Dickinson) along with an intraperitoneal injection of 200 ng pertussis
toxin (List Biological Laboratories Inc.) on the day of immunization and two days later. In
Lewis rats, EAE was induced by intradermal injection at the base of the tail with an emulsion
consisting of 100 μg MBP from guinea pig (Sigma-Aldrich) suspended in CFA with the addi-
tion of 0.2 mg of Mycobacterium Tuberculosis (Becton Dickinson). The animals were moni-
tored daily, weighed and clinically scored according to Table 1. No animals were permitted to
lose more than 20% body weight (compared to the starting point of EAE immunization) and
to go beyond score 4 [20].
Drug administration
At indicated time points (Fig 1), animals were treated daily s.c. either with 1 mg/kg etomoxir
(Meta-IQ ApS) diluted in non-sterile olive oil at 37 ˚C or 200,000 IU IFN-β (Extavia, Aalborg
University Hospital) every other day. The placebo groups received daily injections with saline
or olive oil (non-sterile). Etomoxir is a potent inhibitor of CPT1, which blocks mitochondrial
fatty acid beta-oxidation and exerts its effects on both the adaptive and innate immune
response as well as mobilizing anti-inflammatory effects [21,22].
Immunohistochemical and immunofluorescent staining
Rats were anesthetized with isoflurane and intracardiac perfusion with 0.01M PBS was fol-
lowed by fixation with 4% PFA/PBS (pH 7.4). The brains were isolated and placed for storage
in 4% PFA/PBS at 4 ˚C. Brains were cut into 2 mm thick coronal sections and subjected for
washing procedure in cold running tap water for 4 h and in PBS for following five days at 4 ˚C
with daily exchange of fresh PBS. Sections were dehydrated in ethanol, cleared overnight in
xylene and embedded in paraffin. The paraffin-embedded tissue blocks were cut into 2 μm
thick sections on a rotary microtome (Leica Microsystems), dewaxed, rehydrated and under-
went either peroxidase or fluorescent immunolabeling. Sections were stained for MBP mouse
Table 1. Clinical scoring of animals.
Disease score Clinical symptoms of EAE
0 No clinical signs of EAE
1 Limp tail
2 Paresis of one or two hind limbs
3 Unilateral hind leg paralysis
4 Bilateral hind leg paralysis
5 Bilateral hind leg paralysis and incontinence or moribund
Clinical assessment of animals induced with experimental autoimmune encephalomyelitis (EAE).
https://doi.org/10.1371/journal.pone.0234493.t001
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antibody (1:100, ab62631, Abcam) in connection with goat anti-mouse (1:200, P0447, Dako)
horseradish peroxidase-conjugated secondary antibody and ferritin rabbit antibody (1:500,
ab81444, Abcam) in connection with anti-rabbit antibody (1:200, P0448, Dako) horseradish
peroxidase-conjugated secondary antibody accordingly to the procedure described previously
[23]. Bright field microscopy was carried out using DM5500B microscope (Leica). Immunoflu-
orescence labeling of CPT1A was performed with CPT1A primary mouse antibody (1:100,
ab128568, Abcam) and anti-mouse Alexa fluor 488 secondary antibody (1:200, A21202,
Thermo Fisher). TO-PRO-3 Iodide (1:1000, T3605, Thermo Fisher) was used as the nuclear
counterstain. Whereas, MBP quantification was performed with antibody mentioned earlier in
connection with anti-mouse Alexa fluor 555 secondary antibody (1:200, A-21422, Thermo
Fisher). Laser scanning on confocal microscopy was carried out (Leica DMI6000CS, Wetzlar,
Germany).
Intensity quantification of immunofluorescent labeling
Images designated for fluorescent labeling intensity quantification were taken under the reso-
lution of 1024 x 1024 pixels. Total of 12 images (six from brainstem and six from cerebellum)
from coronal sections at approximately Bergma-13, in possibly similar locations, were
acquired from each etomoxir-treated animal (n = 3) and placebo-treated animal (n = 3). All
other microscopy settings, such as laser power, gain, offset, contrast, gamma values intensity
and pinhole size were kept identical during the whole acquisition process. Single channel gray
scale images were used to assess the integrated density value of CPT1A- and MBP-labeled
Fig 1. Timeline of the experimental autoimmune encephalomyelitis (EAE) models in mice and rats. Mice were
injected with myelin oligodendrocyte glycoprotein (MOG)35-55 and at day 10–12 animals started showing EAE
symptoms. Therefore, treatment with etomoxir (1 mg/kg/day s.c., n = 21) or placebo (n = 21) was initiated at day 10
(a). Rats were injected with myelin basic protein (MBP) and daily treatment of etomoxir (1 mg/kg/day s.c., n = 16) or
placebo (n = 26) was started at day 7 (b). Rats were injected with MBP and treated with etomoxir (1 mg/kg/day s.c.) at
day 1 (n = 10) or day 5 (n = 10), interferon-β (IFN-β) (200,000 IU, every other day, s.c.) day 1 (n = 10) or day 5
(n = 10), or placebo (n = 10) onwards after induction of EAE (c). All studies were terminated when animals showed a
disease score of> 4 or> 20% weight loss.
https://doi.org/10.1371/journal.pone.0234493.g001
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fluorescent sections in ImageJ software after setting a constant threshold level covering desired
labeling.
Intracellular cytokine analysis
Experiments involving human blood samples were carried out in accordance with the
approved guidelines and regulations according to the Declaration of Helsinki. Informed con-
sent forms of these healthy donors have been obtained. The study and use of human blood
material was approved by Ethical Committee for Region North Denmark (N-20150073).
HPBL were isolated, cultured and stained in accordance with Mørkholt et al. [21]. Cells were
stained with FITC mouse anti-human IFN-γ (561057, BD Biosciences), IL-8 (340509, BD Bio-
sciences) or TNF-α (562082, BD Biosciences), and PE mouse anti-human IL-4 (562046, BD
Biosciences) or IL-17α antibodies (560438, BD Bioscience). Cells were analyzed by a FACS
flow cytometer (Beckmann Coulter).
Applied statistics
All statistics were performed using Graph Pad Prism software. Unpaired t tests and ordinary
one-way ANOVA with Tukey´s multiple comparisons post hoc test were used to analyze clini-
cal EAE parameters. Chi-square and Fisher´s exact tests were used to analyze differences in
number of animals showing normal behavioral clinical scores. Two-way ANOVA with either
Tukey´s or Sidak´s multiple comparisons post hoc tests was used to compare clinical score
and weight data over time between the different treatment groups, as well as to compare flow
cytometric expression of cytokines in treated and untreated cells. Expression of CPT1A and
MBP was evaluated by an unpaired t test. Acquired data are presented as mean ± SEM. P val-
ues of 0.05 were considered statistically significant.
Results
Blockage of CPT1 has therapeutic effects in rodent models of EAE
CPT1A is upregulated in the brain lesions of MS patients [13]. As CPT1 is a rate-limiting step
in mitochondrial lipid metabolism of fatty acid beta-oxidation, we tested if blocking of CPT1
with etomoxir (selectively blockage of CPT1 including CPT1A) is effective in the treatment of
EAE progression by reversing functional deficits. EAE was induced by immunization of
C57BL/6 mice (n = 42) and Lewis rats (n = 42 and n = 55) with the myelin oligodendrocyte
glycoprotein (MOG)35-55 peptide and MBP respectively, as described in methods. Ten to
twelve days after immunization, the C57BL/6 mice showed signs of movement disturbances of
the tail and/or hind legs. At this time point (day 10), mice were treated with etomoxir in non-
sterile olive oil or with the placebo (pure non-sterile olive oil) (Fig 1a).
The mice were daily tested for body weight changes and clinical disease scores. After two
weeks of treatment (day 24), the animal study was terminated and the remaining mice were
sacrificed. Five days after the first injection (day 15), the overall mean clinical scores improved
in the etomoxir-treated mice (Fig 2a). There were no significant differences in body weight
between place and etomoxir-treated mice (Fig 2b). The classical EAE parameters showed that
mice treated with etomoxir revealed lower mean maximum EAE score, later mean day of dis-
ease onset and lower disease incidence compared to the placebo group (Fig 2c). Etomoxir
treatment showed a therapeutic effect as 47.6% of mice had normal behavioral scores at day 24
compared to 28.6% in the placebo group (Fig 2c).
The therapeutic efficacy of the treatment was also tested in Lewis rat EAE model using
MBP. Normally, disease onset is seen at day 8 to 9 after disease induction and progresses
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rapidly. Therefore, treatment of the rats with etomoxir or placebo was started at day 7 (Fig 1b)
[24]. Moreover, rats receiving etomoxir exhibited significantly lower disease scores at day 11
compared to the rats receiving placebo (p = 0.0013; two-way ANOVA with Sidak’s post test)
(Fig 3a). Placebo-treated rats showed significantly decreased body weight compared to the eto-
moxir-treated rats (day 9 p = 0.0259; day 10 p = 0.0029; day 11 p = 0.0006; two-way ANOVA
with Sidak’s post test) (Fig 3b). Additionally, etomoxir-treated rats showed significant lower
mean maximum EAE score (p = 0.0236; unpaired t test) and later mean day of onset
(p = 0.0081; upaired t test) compared to the placebo group (Fig 3c). At day 11, none of the pla-
cebo-treated rats showed a normal behavioral score and 73% had already been sacrificed due
to a disease score of 4. In contrast, 25% of the etomoxir-treated rats had normal behavioral
scores, which were highly significant compared to the placebo group (p = 0.0074; chi-square)
(Fig 3c).
Superior therapeutic effects produced by CPT1 inhibition compared to
IFN-β in a rodent model of EAE
CPT1 blockage by etomoxir was compared to interferon-β (IFN-β), as this is one of the current
first-line treatments of MS. Since it has been shown that IFN-β exhibits clinical efficacy in a rat
EAE model when given early, we compared the two pharmacological treatment regimens
when given at day 1 or day 5 after induction of disease (Fig 1c) [25]. This model produced very
severe outcomes, since most of the placebo and IFN-β-treated rats were sacrificed at day 11
due to high disease scores. IFN-β treatment started at day 1 and 5 did not produce therapeutic
Fig 2. Blockage of carnitine palmitoyl transferase 1A (CPT1A) by etomoxir in a mice experimental autoimmune encephalomyelitis
(EAE) model. Two weeks of treatment with etomoxir (1 mg/kg/day s.c., n = 21) compared to placebo (n = 21) treatment of mice with
myelin oligodendrocyte glycoprotein (MOG)35-55-induced EAE. From day 15, etomoxir treatment revealed lower clinical score compared
to animals receiving placebo (a). The average body weight was higher in the mice subjected to etomoxir treatment as compared to placebo-
treated animals (b). Statistically significant differences between etomoxir and placebo mice were not observed for maximum disease score,
disease onset, incidence (c). Data are represented as mean ± SEM.
https://doi.org/10.1371/journal.pone.0234493.g002
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effects, which was the same in the placebo-treated group. In contrast, etomoxir treatment dem-
onstrated therapeutic effects at day 10 when initiated at day 1 compared to placebo, IFN-β at
day 1 and day 5 (placebo p = 0.0347; IFN-β at day 1 p<0.0001; IFN-β at day 5 p = 0.0004; two-
way ANOVA with Sidak’s post test) (Fig 4a), and when started at day 5 compared to IFN-β at
day 1 and day 5 (IFN-β at day 1 p = 0.0004; IFN-β at day 5 p = 0.0046; two-way ANOVA with
Sidak’s post test) (Fig 4a). Additionally, at the last day rats treated with etomoxir at day 1
exhibited lower disease scores compared to animals receiving placebo (p = 0.0133), IFN-β at
day 1 (p = 0.0004) and IFN-β at day 5 (p = 0.0133) (Fig 4a). Rats started treatment with eto-
moxir at day 5 showed significantly lower disease score compared to IFN-β at day 1
(p = 0.0133; two-way ANOVA with Sidak’s post test) (Fig 4a). Etomoxir, however, did not sig-
nificantly affect the body weight over time (Fig 4b). Moreover, etomoxir treatment initiated at
day 1 revealed a significant lower mean maximum EAE score compared to IFN-β at day 1
(p = 0.0102; one-way ANOVA with Tukey´s post test) (Fig 4c).
Etomoxir decreases CPT1A expression and improves myelination and
ferritin deposits
Immunohistochemistry provided additional evidence for the therapeutic effect of etomoxir
treatment compared to the placebo group in the rat EAE model. Etomoxir-treated rats had
Fig 3. Blockage of carnitine palmitoyl transferase 1A (CPT1A) by etomoxir in a rat experimental autoimmune encephalomyelitis
(EAE) model. Rats were subjected to myelin basic protein (MBP)-induced EAE and treated either with etomoxir (1 mg/kg/day s.c.,
n = 16.) or placebo (n = 26). Etomoxir-treated rats exhibited significantly lower disease scores at day 11 compared to rats receiving placebo
analyzed by a two-way ANOVA with Sidak’s multiple comparisons post hoc tests (a). The results from the two-way ANOVA with Sidak’s
multiple comparisons post hoc test showed significantly higher body weight in the rats subjected to etomoxir treatment as compared to
placebo-treated animals at day 9, 10 and 11 (b). Statistically significant differences between etomoxir and placebo treated rats were
observed for maximum disease score and disease onset (unpaired t test) (c). Etomoxir treatment resulted in 25% of the rats showing
normal behavioral scores compared to 0% after placebo treatment analyzed by a Fisher´s exact test (c). Data are represented as
mean ± SEM. Number of asterisks indicates the level of statistical significance (�p< 0.05, ��p< 0.01, ���p< 0.001).
https://doi.org/10.1371/journal.pone.0234493.g003
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markedly increased intensity of MBP labeling with no evident pathological lesions (Fig 5a–5d),
particularly pronounced in the cerebellum (Fig 5b–5d) when compared with placebo-treated
rats (Fig 5e–5h). In the cerebellum of etomoxir-treated rats, MBP labeling in the white matter
was more intense compared with placebo-receiving rats (Fig 5b and 5f). Similarly, in the eto-
moxir group, more intense MBP labeling was noted in granular and molecular cerebellar lay-
ers in the form of fibrous bundles protruding from the white matter (Fig 5c and 5d). Whereas,
in the placebo group, characteristic MBP-labeled fibrous bundles were sparse and labeling pat-
tern was more dotted with barely noticeable threadlike structure (Fig 5g and 5h). In the brain-
stem, differences in MBP labeling intensity were less evident than that of cerebellum.
Nevertheless, in the etomoxir-treated group, MBP-labeled fibrous structures laterally
Fig 4. Comparing the effects of etomoxir and interferon-β (IFN-β) in a rat experimental autoimmune encephalomyelitis (EAE) model.
Rats were subjected to myelin basic protein (MBP)-induced EAE and treated either with etomoxir (1 mg/kg/day s.c.) at day 1 (n = 10) or day
5 (n = 10), IFN-β (200,000 IU s.c.) every other day from day 1 (n = 10) or day 5 (n = 10), or placebo (n = 10) onwards after EAE induction.
Results from the RM two-way ANOVA with Tukey’s multiple comparisons post hoc test showed that rats receiving etomoxir at day 1 and day
5 exhibited significantly lower disease scores compared to IFN-β day 1, IFN-β day 5 and placebo at day 10 and 11 (a). The average body
weight was higher in etomoxir-treated rats compared to IFN-β-treated animals, though this was not significant (b). Statistically significant
difference between etomoxir and IFN-β both initiated at day 1 was observed for maximum disease score (unpaired t test) (c). Data are
represented as mean ± SEM. Number of asterisks indicates the level of statistical significance (�p< 0.05, ��p< 0.01, ���p< 0.001,
����p< 0.0001).
https://doi.org/10.1371/journal.pone.0234493.g004
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protruding from the nucleus raphe magnus and the medial longitudinal fascicle (Fig 5a) were
labeled more intensely than in the placebo group (Fig 5e).
Immunofluorescent signal intensity of CPT1A in paraffin-embedded brain sections from
etomoxir-treated rats was significantly lower in both brainstem (p = 0.0083; unpaired t-test)
and cerebellum (p = 0.0237; unpaired t test) compared to the placebo group (Fig 6a–6c), con-
firming the downregulation of CPT1 in etomoxir-treated group. These data showed that
blocking CPT1, which specifically blocks the metabolism of lipids, produced therapeutic
Fig 5. Immunoperoxidase microscopy of myelin basic protein (MBP) in coronal brainstem and cerebellum of etomoxir-treated rats (a-d) and placebo rats
(e-h). The etomoxir-treated group shown to possess higher MBP-labeling in the brainstem visualized as fibrous structures laterally protruding from nucleus
raphe magnus and medial longitudinal fascicle compared to the group receiving placebo (a and e). Likewise, in the cerebellar white matter of etomoxir-treated
rats, MBP-labeling was markedly more intense compared with placebo-receiving rats (b and f). MBP axons ensheathing in etomoxir-treated rats was labeled in
the form of fibrous bundles in the cerebellar white matter, granular and molecular cerebellar layers, whereas in placebo animals MBP-labeled fibrous bundles
were sparse and labeling pattern was more (c,d,g and h).
https://doi.org/10.1371/journal.pone.0234493.g005
Fig 6. Immunofluorescent images of carnitine palmitoyl transferase 1A (CPT1A) in placebo-receiving rats (n = 3) (a) and etomoxir-treated rats (n = 3)
(b). CPT1A signal intensity was significantly lower in both cerebellum and brainstem of the etomoxir-treated animals compared to the placebo-treated
animals illustrating the blocking effect of etomoxir treatment (c). CPT1A was labeled with green and TO-PRO-3 was used as nuclei counterstain overlaid
with blue color. Data are represented as mean ± SEM. Number of asterisks indicates the level of statistical significance (�p< 0.05, ��p< 0.01).
https://doi.org/10.1371/journal.pone.0234493.g006
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effects in the animal models of MS. Consequently, fluorescent MBP quantification have con-
firmed qualitative peroxidase-labeling (Fig 7a and 7b) and showed significantly higher level of
MBP-labeling in the cerebellum (p = 0.0192; unpaired t test) with matching trend in the brain-
stem (Fig 7c).
Rats receiving etomoxir showed reduced ferritin labeling in the brainstem and cerebellum
when compared to the placebo group (Fig 8a–8d). In the cerebellum and brainstem of eto-
moxir-treated rats, ferritin labeling was noticed mostly around blood vessels (Fig 8a and 8c),
whereas in the placebo group labeling was readably more intense and noticed also around and
inside the cells (presumably neurons) (Fig 8b and 8d).
Additionally, MBP fluorescent labeling together with TO-PRO-3 nuclei stain was used to
illustrate immune cell infiltration. Among sections from etomoxir-treated rats cell aggrega-
tions with readably decreased MBP-labeling surrounding them had not been encountered (Fig
9a), whereas in the sections from placebo-receiving rats described cellular aggregates that were
encountered especially in the brainstem (Fig 9b and 9c).
Decreased IFN-γ and IL-17α expression in activated T cells after etomoxir
treatment
In MS, the pro-inflammatory immune response is associated with disease pathogenesis [26–
28], therefore the effect of etomoxir on the inflammatory response was also investigated.
Human peripheral blood lymphocytes were stimulated with staphylococcus enterotoxin B
(SEB) for 48 h in the presence or absence of 100 μM etomoxir. After incubation, the cytokine
expression was measured by intracellular flow cytometry. Etomoxir blocked the production of
interferon-γ (IFN-γ) (58%), interleukin-8 (IL-8) (11%), interleukin-17α (IL-17α) (64%) and
the tumor necrosis factor-α (TNF-α) (55%). A small increase of interleukin-4 (IL-4) (27%)
production was observed. The T cell response was directed from a Th1, Th17α response to a
Th2 type T cell response. Etomoxir also mediated significantly increase in IL-4 production and
decrease in IL-17α production (IL-4 p = 0.0065; IL-17α p = 0.0102; two-way ANOVA with
Tukey’s post test) (Fig 10).
Discussion
For a long time MS has been regarded as an autoimmune disease, where the immune system
has been proposed as the primary cause of the disease. Most treatment strategies have been
Fig 7. Immunofluorescent images of myelin basic protein (MBP)-labeling in the brainstem of placebo-receiving rats (n = 3) (a) and etomoxir-treated
rats (n = 3) (b). MPB-labeling was significantly higher in the cerebellum of etomoxir-treated rats and represented similar tendency in the brainstem,
though this was not statistical significantly changed (c). MBP was visualized with Alexa fluor 555 antibody and overlaid with magenta color, whereas
nuclear counterstain TO-PRO-3 was overlaid with cyan. Data are represented as mean ± SEM. Number of asterisks indicates the level of statistical
significance (�p< 0.05).
https://doi.org/10.1371/journal.pone.0234493.g007
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Fig 8. Immunoperoxidase staining of ferritin in cerebellum and brainstem from etomoxir-treated rats and
placebo-receiving rats. Rats receiving etomoxir showed reduced ferritin labeling in both brainstem (a) and cerebellum
(c) when compared to the placebo group, respectively (b and d). In the placebo group vastly more intense labeling was
noticed around blood vessels and noticed also around and inside the cells (presumably neurons) (b and d).
https://doi.org/10.1371/journal.pone.0234493.g008
Fig 9. Myelin basic protein (MBP) fluorescent labeling together with TO-PRO-3 nuclei stain illustrating immune cell infiltration in etomoxir-treated
rats (n = 3) and placebo-receiving rats (n = 3). In the sections from placebo-receiving rats, TO-PRO-3-labeled cellular aggregates were encountered
especially in the brainstem (indicated by arrows in b and c) and surrounded with decreased level of MBP-labeling. There were very spars cell aggregations
in the sections from etomoxir-treated rats (a). MBP was visualized with Alexa fluor 555 antibody and overlaid with magenta color, whereas nuclear
counterstain TO-PRO-3 was overlaid with cyan.
https://doi.org/10.1371/journal.pone.0234493.g009
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focused solely on the modulation of the inflammatory component of the disease. Thus far,
these treatments have been successful in suppressing or delaying relapsing episodes in relaps-
ing-remitting MS and primary-relapsing MS. However, these interventions have not brought
an obvious therapeutic effect on disease progression, particularly for the treatment of primary-
progressive MS and secondary-progressive MS.
Consistent with the results demonstrated by Lieury et al. [13], we have found that CPT1A is
upregulated in MS and EAE lesions. Compared to the normal healthy brain, the mean CPT1A
expression is 179% in active MS plaque, 140% in chronic active plaque and 124% in chronic
plaque (NCBI Geo Profiles). Moreover, the key role of CPT1A in MS is supported by studies
regarding CPT1A mutations in humans. Two types of loss-of-function mutation in CPT1A,
which inhibits the activity of the enzyme, have been identified in humans (Hutterite and Inuit
populations) [29–31]. Common for both populations is highly reduced MS frequency com-
pared to the Canadian population [32,33]. A study with mice having the CPT1A mutation
mimicking the Inuit mutation is supporting this key role of CPT1a in the development of
EAE, since these mice were resistant to EAE development [34].
Approximately 70% of brain tissue is comprised of lipids and thereby lipids are one of the
most important components of the brain. Lipids constitute the myelin sheath, which is impor-
tant for efficient transmission of signals through neurons with high speed and low energy. The
half-life of these myelin lipids is approximately three days [35]. This replacement occurs effi-
ciently in healthy brain tissues through maintenance of high lipid levels by the oligodendro-
cytes. In MS, however, CPT1A is upregulated, leading to lipid catabolism through accelerated
beta-oxidation, as described by Lieury et al. [13]. This finding was further confirmed by evi-
dence of decreased lipid levels in association with disease progression [3,36–38]. The loss of
lipids in myelin exposes a citrullinated MBP (deamination of arginine to citrulline), which, in
turns, increases the inflammatory and immune responses (both B and T cells) due to PGE2
production [14–17,39]. Thus, the neurites are slowly stripped from the protective myelin
sheath. This inflammatory response in EAE can be blocked by etomoxir [40].
With conditions of stress (physical, pathological, psychological or immunological) follows a
state of hypoxia in the brain, which causes the metabolism to shift locally from a glucose-based
to a lipid-based metabolism. This will have an effect on the balance in the peroxisome
Fig 10. Intracellular cytokine analysis of etomoxir-treated Staphylococcal enterotoxin B (SEB)-stimulated human
peripheral blood lymphocytes. Etomoxir revealed the lower percentage of positive cells for interferon-γ (IFN-γ),
tumor necrosis factor-α (TNF-α) and interleukin-17α (IL-17α), but induced increased percent positive cells for
interleukin-8 (IL-8) and interleukin (IL-4). Results were analyzed by a two-way ANOVA with a Tukey multiple
comparison post hoc tests. Data are represented as mean ± SEM. Number of asterisks indicates the level of statistical
significance (�p< 0.05, ��p< 0.01).
https://doi.org/10.1371/journal.pone.0234493.g010
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proliferator-activated receptor (PPAR) network [3]. Additionally, due to favored lipid metabo-
lism the insulin receptor will become insensitive, furthering the lipid metabolism [41]. This
process will particularly have an effect on the CNS as lipids play an important role in signal
propagation and minimizing energy expenditure. The hypothalamic-pituitary-adrenal (HPA)
axis will be hyper-activated and stimulating an immune response at the site of lipid metabo-
lism, resulting in an immune attack on the myelin sheath proteins and oligodendrocytes
[42,43]. Therefore, by blocking CPT1 with etomoxir, the inflammatory response will be down-
regulated and the lipid metabolism will be blocked resulting in restoration of glucose metabo-
lism, increased insulin sensitivity, and restoration of the PPAR balance and HPA axis.
We hypothesized that the optimal treatment regimen for MS would be to block the runaway
lipid catabolism, thereby maintaining or increasing lipid levels in the brain and brainstem.
More lipids can then be used by oligodendrocytes to restore the altered lipidation of the myelin
sheaths, restoring neuronal functions. As lipids are important in both building the myelin
sheath and the activation of memory B and T cells, the inhibition of lipid catabolism blocks
memory and inflammatory immune responses, leaving the regulatory immune response
intact.
We demonstrated that inhibition of lipid catabolism by blocking CPT1 in animal models of
EAE reverses disease progression (Figs 2, 3 and 4). In addition, comparison of CPT1A labeling
fluorescent signal intensity in brain sections of EAE-induced rats resulted in significantly
lower signal intensity in the etomoxir-treated rats versus the placebo group, thus confirming
downregulated CPT1 levels after etomoxir treatment (Fig 6). Significant downregulation of
CPT1A had occurred together with the markedly higher intensity of MPB labeling in cerebel-
lum and brainstem (Fig 7). Consequently, improved MPB labeling in the cerebellum of eto-
moxir-treated rats (Fig 5) corresponded well with their lower clinical scores. Inhibition of
CPT1 demonstrated effect on the ferritin levels, visualized by reduction in staining in the eto-
moxir-treated animals compared to the placebo group (Fig 8). Ferritin signals iron deposits
which are a result of mitochondrial dysfunction [44,45]. The decreased brain metabolism
together with dysfunctional mitochondria promote an environment for enhances oxidative
stress. A study has demonstrated that the severity of EAE correlates with the gene expression
of genes involved in oxidative stress, such as HO-1 and NOX2 [34]. Moreover, blocking lipid
metabolism by etomoxir decreased the Th1 and Th17 inflammatory responses, which have
been shown to be involved in the MS development [26–28]. Similarly, our results have shown
much lower occurrence of cellular aggregates presumably belonging to immune infiltrates,
encircled with increased MBP levels in the brainstem of etomoxir-treated rats (Fig 9). After
two weeks of treatment in mice suffering from EAE, 47.6% of the mice had normal behavioral
scores (Fig 2c) and in the rat EAE model, 25% of the etomoxir-treated animals had normal
behavioral scores when treatment was started at day 7 (Fig 3c). The etomoxir-treated rats
exhibited statistically significant lower clinical scores and body weight over time compared to
the placebo group (Fig 3a and 3b). Furthermore, etomoxir-treated rats showed significantly
later disease onset (13.69 ± 1.54) compared to the placebo group (10.31 ± 0.13). Comparing
the treatment efficacy between etomoxir and IFN-β (the first line of medicine given currently
to MS patients) showed that IFN-β treatment was ineffective at 1 or 5 days after induction of
the disease in animals with EAE, whereas etomoxir had very pronounced efficacy by signifi-
cantly lowering the clinical scores of the animals compared to animals receiving IFN-β day 1
and 5, and placebo (Fig 4a). Moreover, the maximum EAE score for rats treated with etomoxir
initiated day 1 were significantly reduced compared to IFN-β day 1 (Fig 4c).
The overall conclusion from the presented data is that suppression of the enhanced lipid
catabolism and beta-oxidation through CPT1A inhibition could provide therapeutic effects
against MS. This may be assumed since the EAE model is a state-of-art in vivo animal model of
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MS. It shows similarities to MS by both clinical and pathological features, and reveal the com-
plex interaction of demyelination, inflammation, axonal loss and gliosis. On the other hand,
there are some limitations by using EAE to investigate MS relations such as viruses (e.g.
Epstein-Barr virus), psychological and social factors since these cannot be modelled properly
in animal models. However, many of the drugs available for MS today have been developed
and validated in studies using the EAE model [19].
In conclusion, the proposed metabolic switch from glucose to lipid could provide an expla-
nation to the pathogenesis of MS, based on the data from our EAE experiments where block-
ing the metabolism of lipids stops disease progression. When the lipidation of the myelin
sheath is defective, the blockage of an inflammatory response by common disease modifying
drugs such as IFN-β can only slow down the disease progression. Thus our experiments with
etomoxir not only provide a new avenue of treatment, but also provide new evidence for a par-
adigm shift when thinking about the pathophysiology of MS. Our data show that MS should
be considered as a systemic disease, where altered lipid metabolism in the myelin sheath plays
a primary role, and the immune system is the aggravating factor. Moreover, this approach will
provide a new insight into therapeutic approaches for other neurodegenerative diseases such
as Alzheimer´s disease and Parkinson´s disease, as well as Amyotrophic lateral sclerosis.
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